会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • CAROTENOID ANALOGS OR DERIVATIVES FOR THE INHIBITION AND AMELIORATION OF INFLAMMATION
    • 用于抑制和改善炎症的毛细血管细胞模拟物或衍生物
    • WO2007027834A1
    • 2007-03-08
    • PCT/US2006/033948
    • 2006-08-29
    • CARDAX PHARMACEUTICALS INC.LOCKWOOD, Samuel, FournierO'MALLEY, SeanJACKSON, HenryNADOLSKI, Geoff
    • LOCKWOOD, Samuel, FournierO'MALLEY, SeanJACKSON, HenryNADOLSKI, Geoff
    • A61K31/661A61K31/6615A61K31/225A61P35/00A61P11/06A61P29/00
    • A61K31/015A61K31/12A61K31/225A61K31/66A61K31/661A61K31/6615
    • A method for inhibiting and/or ameliorating the occurrence of diseases in a human subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative. In some embodiments, the administration of analogs or derivatives of carotenoids may inhibit and/or ameliorate the occurrence of diseases in subjects. In some embodiments, analogs or derivatives of carotenoids may be water-soluble and/or water dispersible. Maladies that may be treated with analogs or derivatives of carotenoids embodied herein may include diseases that provoke or trigger an inflammatory response. In an embodiment, asthma may be treated with analogs or derivatives of carotenoids embodied herein. In an embodiment, administering analogs or derivatives of carotenoids embodied herein to a subject may control or affect the bioavailability of eicosanoids. In an embodiment, atherosclerosis may be treated with analogs or derivatives of carotenoids embodied herein. In an embodiment, administering the analogs or derivatives of carotenoids embodied herein to a subject may control or affect the bioavailability of 5-LO-catalyzed eicosanoid metabolites. In an embodiment, 5-LO-catalyzed eicosanoid metabolites that may be controlled or affected by administering analogs or derivatives of carotenoids to a subject may include proinflammatory effector molecules (e.g., leukotrienes).
    • 一种抑制和/或改善人类受试者中疾病发生的方法,其中受试者单独或与另一种类胡萝卜素类似物或衍生物组合施用类胡萝卜素类似物或衍生物。 在一些实施方案中,类胡萝卜素类似物或衍生物的施用可以抑制和/或改善受试者中疾病的发生。 在一些实施方案中,类胡萝卜素的类似物或衍生物可以是水溶性的和/或水分散的。 可用本文体现的类胡萝卜素类似物或衍生物治疗的疟疾可能包括引发或触发炎性反应的疾病。 在一个实施方案中,可以用本文所体现的类胡萝卜素类似物或衍生物来治疗哮喘。 在一个实施方案中,将本文体现的类胡萝卜素的类似物或衍生物施用于受试者可以控制或影响类花生酸的生物利用度。 在一个实施方案中,可以用本文所体现的类胡萝卜素类似物或衍生物来治疗动脉粥样硬化。 在一个实施方案中,将本文体现的类胡萝卜素的类似物或衍生物施用于受试者可以控制或影响5-LO催化的类花生酸酯代谢物的生物利用度。 在一个实施方案中,可以通过向受试者施用类胡萝卜素的类似物或衍生物来控制或影响的5-LO-催化的类花生酸代谢物可以包括促炎效应分子(例如白三烯)。
    • 3. 发明申请
    • CAROTENOID ANALOGS OR DERIVATIVES FOR THE INHIBITION AND AMELIORATION OF INFLAMMATION
    • 用于抑制和改善炎症的毛细血管细胞模拟物或衍生物
    • WO2005102356A1
    • 2005-11-03
    • PCT/US2005/012811
    • 2005-04-14
    • HAWAII BIOTECH, INC.LOCKWOOD, Samuel, F.O'MALLEY, SeanJACKSON, HenryNADOLSKI, Geoff
    • LOCKWOOD, Samuel, F.O'MALLEY, SeanJACKSON, HenryNADOLSKI, Geoff
    • A61K31/6615
    • A61K31/015A61K31/12A61K31/225A61K31/341A61K31/66A61K31/6615
    • A method for inhibiting and/or ameliorating the occurrence of diseases in a human subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative. In some embodiments, the administration of analogs or derivatives of carotenoids may inhibit and/or ameliorate the occurrence of diseases in subjects. In some embodiments, analogs or derivatives of carotenoids may be water-soluble and/or water dispersible. Maladies that may be treated with analogs or derivatives of carotenoids embodied herein may include diseases that provoke or trigger an inflammatory response. In an embodiment, asthma may be treated with analogs or derivatives of carotenoids embodied herein. In an embodiment, administering analogs or derivatives of carotenoids embodied herein to a subject may control or affect the bioavailability of eicosanoids. In an embodiment, atherosclerosis may be treated with analogs or derivatives of carotenoids embodied herein. In an embodiment, administering the analogs or derivatives of carotenoids embodied herein to a subject may control or affect the bioavailability of 5-LO-catalyzed eicosanoid metabolites. In an embodiment, 5-LO-catalyzed eicosanoid metabolites that may be controlled or affected by administering analogs or derivatives of carotenoids to a subject may include proinflammatory effector molecules (e.g., leukotrienes).
    • 一种抑制和/或改善人类受试者中疾病发生的方法,其中受试者单独或与另一种类胡萝卜素类似物或衍生物组合施用类胡萝卜素类似物或衍生物。 在一些实施方案中,类胡萝卜素类似物或衍生物的施用可以抑制和/或改善受试者中疾病的发生。 在一些实施方案中,类胡萝卜素的类似物或衍生物可以是水溶性的和/或水分散的。 可用本文体现的类胡萝卜素类似物或衍生物治疗的疟疾可能包括引发或触发炎性反应的疾病。 在一个实施方案中,可以用本文所体现的类胡萝卜素类似物或衍生物来治疗哮喘。 在一个实施方案中,将本文体现的类胡萝卜素的类似物或衍生物施用于受试者可以控制或影响类花生酸的生物利用度。 在一个实施方案中,可以用本文所体现的类胡萝卜素类似物或衍生物来治疗动脉粥样硬化。 在一个实施方案中,将本文体现的类胡萝卜素的类似物或衍生物施用于受试者可以控制或影响5-LO催化的类花生酸酯代谢物的生物利用度。 在一个实施方案中,可以通过向受试者施用类胡萝卜素的类似物或衍生物来控制或影响的5-LO-催化的类花生酸代谢物可以包括促炎效应分子(例如白三烯)。